Savara Inc - Asset Resilience Ratio
Savara Inc (SVRA) has an Asset Resilience Ratio of 76.71% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Savara Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Savara Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $108.11 Million | 76.71% |
| Total Liquid Assets | $108.11 Million | 76.71% |
Asset Resilience Insights
- Very High Liquidity: Savara Inc maintains exceptional liquid asset reserves at 76.71% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Savara Inc Industry Peers by Asset Resilience Ratio
Compare Savara Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 2.21% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.34% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
Annual Asset Resilience Ratio for Savara Inc (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Savara Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 85.12% | $181.20 Million | $212.88 Million | +8.68pp |
| 2023-12-31 | 76.44% | $135.73 Million | $177.56 Million | +23.66pp |
| 2022-12-31 | 52.78% | $73.78 Million | $139.78 Million | -19.22pp |
| 2021-12-31 | 72.00% | $127.16 Million | $176.60 Million | +11.33pp |
| 2020-12-31 | 60.68% | $59.31 Million | $97.75 Million | +7.85pp |
| 2019-12-31 | 52.83% | $71.96 Million | $136.20 Million | -3.99pp |
| 2018-12-31 | 56.82% | $86.53 Million | $152.29 Million | +11.59pp |
| 2017-12-31 | 45.23% | $72.19 Million | $159.63 Million | +35.76pp |
| 2016-12-31 | 9.47% | $2.74 Million | $28.93 Million | -23.60pp |
| 2015-12-31 | 33.07% | $17.93 Million | $54.22 Million | +2.60pp |
| 2014-12-31 | 30.47% | $21.48 Million | $70.50 Million | -3.40pp |
| 2013-12-31 | 33.87% | $18.71 Million | $55.25 Million | +4.04pp |
| 2012-12-31 | 29.83% | $14.01 Million | $46.97 Million | +18.30pp |
| 2011-12-31 | 11.53% | $7.13 Million | $61.86 Million | -42.55pp |
| 2007-12-31 | 54.09% | $18.68 Million | $34.54 Million | +5.28pp |
| 2006-12-31 | 48.81% | $25.77 Million | $52.80 Million | +15.12pp |
| 2005-12-31 | 33.69% | $7.96 Million | $23.62 Million | -- |
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.